High time for low-dose prospective clinical trials

The article by Glode et al. in this issue reports on the empiric success, as defined by a decreased prostate specific antigen level and lack of toxicity, of metronomically delivered low-dose chemotherapy for patients with hormone-refractory prostate carcinoma. The data presented were collected as a retrospective evaluation of the medical records of patients treated with cyclophosphamide and dexamethasone who were unable to participate in Phase II drug trials or had failed previous chemotherapy regimens.